10.95
13.94%
1.34
Gh Research Plc stock is traded at $10.95, with a volume of 94,500.
It is up +13.94% in the last 24 hours and up +31.77% over the past month.
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. The company is focused on developing novel and proprietary Mebufotenin 5-Methoxy-N, N-Dimethyltryptamine, or 5-MeO-DMT, therapies for the treatment of patients with Treatment-Resistant Depression, or TRD.
See More
Previous Close:
$9.61
Open:
$9.59
24h Volume:
94,500
Relative Volume:
1.73
Market Cap:
$543.17M
Revenue:
-
Net Income/Loss:
$-32.32M
P/E Ratio:
-15.94
EPS:
-0.687
Net Cash Flow:
$-36.14M
1W Performance:
+18.51%
1M Performance:
+31.77%
6M Performance:
-17.55%
1Y Performance:
+77.18%
Gh Research Plc Stock (GHRS) Company Profile
Compare GHRS with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
GHRS | 10.95 | 543.17M | 0 | -32.32M | -36.14M | -0.687 |
VRTX | 451.23 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 743.35 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 591.82 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 248.79 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 102.14 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Gh Research Plc Stock (GHRS) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Aug-16-22 | Initiated | H.C. Wainwright | Buy |
Jun-16-22 | Initiated | ROTH Capital | Buy |
Gh Research Plc Stock (GHRS) Latest News
H.C. Wainwright maintains buy rating on GHRS shares, cites Q3 report - Investing.com
GH Research (NASDAQ:GHRS) Trading Up 2%Time to Buy? - MarketBeat
3 Fast-Growing Stocks Analysts See Doubling in Price - MSN
Does GH Research (GHRS) Have the Potential to Rally 225.18% as Wall Street Analysts Expect? - Yahoo Finance
GH Research (NASDAQ:GHRS) Given Buy Rating at HC Wainwright - MarketBeat
Canaccord Genuity Group Issues Pessimistic Forecast for GH Research (NASDAQ:GHRS) Stock Price - Defense World
GH Research Q3 2024 Results and Clinical Updates - TipRanks
GH Research (NASDAQ:GHRS) Trading 1.2% HigherTime to Buy? - MarketBeat
Short Interest in GH Research PLC (NASDAQ:GHRS) Increases By 7.3% - MarketBeat
GH Research (NASDAQ:GHRS) Stock Price Up 3.3%Here's Why - MarketBeat
GH Research shares hold Buy rating as Canaccord anticipates pivotal durability data in 2025 - Investing.com
GH Research (NASDAQ:GHRS) Price Target Lowered to $28.00 at Canaccord Genuity Group - MarketBeat
GH Research (NASDAQ:GHRS) Stock Price Up 0.1%Time to Buy? - MarketBeat
RA Capital Management, L.P. Increases Stake in GH Research PLC - GuruFocus.com
Health Stocks Slide as Trump Picks Industry Skeptic Kennedy - BNN Bloomberg
GH Research reports deeper losses as DMT clinical trial costs mount - Green Market Report
GH Research (NASDAQ:GHRS) Shares Up 0.2%Here's What Happened - MarketBeat
Lynx1 Capital Management LP's Strategic Acquisition in GH Resear - GuruFocus.com
GH Research Reports Third Quarter 2024 Financial Results and Provides Business Updates - GlobeNewswire
GH Research Completes Phase 2b Depression Trial Enrollment, Reports $12.1M Q3 Loss | GHRS Stock News - StockTitan
GH Research (NASDAQ:GHRS) Stock Price Up 3.8%Here's Why - MarketBeat
GH Research (NASDAQ:GHRS) Stock Price Up 4.1%Still a Buy? - MarketBeat
(GHRS) Pivots Trading Plans and Risk Controls - Stock Traders Daily
GH Research (NASDAQ:GHRS) Trading 3.1% HigherHere's What Happened - MarketBeat
Intellia Thera CS (NTLA-Q) QuotePress Release - The Globe and Mail
Guardant Health, Inc. (NASDAQ:GH) Shares Acquired by US Bancorp DE - Defense World
We Think GH Research (NASDAQ:GHRS) Can Afford To Drive Business Growth - Yahoo Finance
GH Research (NASDAQ:GHRS) Trading Up 0.6%What's Next? - MarketBeat
Major Depressive Disorder Clinical Trials 2024: FDA Approvals, - openPR
GH Research (NASDAQ:GHRS) Trading Down 0.9%Should You Sell? - MarketBeat
GH Research (NASDAQ:GHRS) Trading Up 2.1%What's Next? - MarketBeat
GH Research (NASDAQ:GHRS) Stock Price Up 0.6%Here's Why - MarketBeat
GH Research (NASDAQ:GHRS) Trading Up 0.7%Here's What Happened - MarketBeat
abrdn plc Raises Stock Holdings in Guardant Health, Inc. (NASDAQ:GH) - MarketBeat
(GHRS) On The My Stocks Page - Stock Traders Daily
GH Research (NASDAQ:GHRS) Shares Up 2.2%Time to Buy? - MarketBeat
Standard Chartered Bank Ghana PLC (SCB.gh) Q32024 Interim Report - AfricanFinancials
GH Research PLC (NASDAQ:GHRS) Sees Significant Growth in Short Interest - MarketBeat
GH Research (NASDAQ:GHRS) Shares Down 1%What's Next? - MarketBeat
GH Research (NASDAQ:GHRS) Shares Up 2.8%Here's What Happened - MarketBeat
GH Research (NASDAQ:GHRS) Trading Down 0.1%Here's Why - MarketBeat
Acromegaly Market Innovations Investigated by Size, Share, Trends And Outlook Report 2024-2033 - WhaTech
Psychedelic Drugs Industry Size, Growth Opportunities - openPR
GH Research (NASDAQ:GHRS) Trading 3.3% HigherHere's Why - MarketBeat
How To Trade (GHRS) - Stock Traders Daily
Stanbic Bank facilitates GH¢200m bond issuance for Kasapreko PLC - Graphic Online
GGBL announces dividend of GH¢0.022 per share for shareholders - Myjoyonline
Objective long/short (GHRS) Report - Stock Traders Daily
Tullow Oil Plc (TLW.gh) HY2024 Presentation - AfricanFinancials
When (GHRS) Moves Investors should Listen - Stock Traders Daily
Mackenzie Financial Corp Has $148.34 Million Holdings in Ferguson plc (NASDAQ:FERG) - Defense World
Gh Research Plc Stock (GHRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):